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ADVANCES IN PHARMACOLOGY
An Evidence-Based Update On Vitamins
K. Kelly Orr, PharmD, and Anne L. Hume, PharmD, FCCP, BCPS
In the United States, dietary suppiements inciude vitamins,
minerals, amino acids, herbal and nonboranical produces such
as melatonin, as well as certain types of foods. Vitamins remain
the most common type of dietary supplement used by otherwise
healthy adults. Vitamins are available as single entity products,
mixtures such as B complex or antioxidant products, multivita-
mins (MV) which frequently contain 10 or more vitamins, and
multivitamin muJtiminerals (MVMM) which may include over
20 different vitamins and minerals. This article summarizes the
evidence on the use of multivitamin and single vitamin products
among healthy individuáis without documented deficiencies.
MULTIVITAMIN PRODUCTS
An estimated 35% to 50% of Americans regularly take
MVMM products,''^ even though vitamin and mineral deficien-
cies are uncommon among otherwise healthy adults, with the ex-
ception of vitamin D and iron. Use is most common among women,
older adults, and nonhispanic whites and frequently for the pur-
pose of preventing chronic diseases. Other prediaors of use include
having higher levels of education, physical activity, and overall
healthier diets. In feet, studies demonstrating modest health ben-
efits may actually represent unmeasured healthy behaviors.
Many studies have evaluated the potential benefits of MV
or MVMM products. One recent study, using data from the
clinical and observational trials of the Womens Health Initia-
tive, identified vitamin use at baseline and at follow-up visits over
8 years. Use of MV, MVMM, or high-dose multivitamin supple-
ments was not associated with reduced risk of eight common
cancers, cardiovascular disease (CVD), or total mortality.' Al-
though orher clinical trials, such as the Physicians' Health Study
II, are evaluating the effects of MV use on cancer, CVD, eye
disease, and cognitive status, little evidence supports the use of
MV or MVMM products in otherwise healthy adults.
VITAMIN A
The best evidence for the use of vitamin A, as beta-carotene, is
for the prevention of age-related macular degeneration. The Age-
Related Eye Disease Study (AREDS) Research Group has recom-
mended an antioxidant combination including 15 mg beta-caro-
tene in individuals over 55 years of age who are at risk of developing
macular degeneration. Other components in the AREDS formula-
tion include vitamin C, vitamin E, zinc, and copper.^
Although a diet of fruits and vegetables rich in vitamin A
has been associated with a reduction in cancer risk, two earlier
cancer prevention trials identified safety concerns with beta-caro-
tene supplements. The Alpha-Tocopherol, Beta-Carotene
(ATBC) Cancer Prevention Study Group and Beta-Carotene
and Retinol Efficacy Trial (CARET) found an increase in lung
cancer and overall mortality in current or former smokers taking
beta-carotene and/or vitamin A (retinyl palmitate).*"'' Several "eye
health" formulations omit vitamin A and are marketed specifi-
cally towards current and former smokers.
Consumers should be avrare of the potential adverse effects
from excess vitamin A consumption. In doses over 50,000 lU,
acute toxicity may manifest as headaches, blindness, increased
intracranial pressure, nausea, vomiting, and lack of muscular co-
ordination. Because vitamin A exposure may result in craniofa-
cial, cardiovascular, and central nervous system malformations,
pregnant women should not consume more than 5,000 IU per
day. In addition, other evidence In adults su^ests higher retino!
concentrations may he associated with reduced bone mineral
density and an increased risk of hip fracture by impairing the
effect of vitamin D on calcium absorption."
Vitamin A is In many over-the-counter (OTC) products not
commonly associated with vitamins. Original Airborne Zesty Or-
ange contains 2,000 IU vitamin A (retinyl palmitate) to be taken
up to three times daily as needed. Airborne Iriple Pack Zesty Or-
ange, has 5,000 IU vitamin A (retinjH acetate) in each tablet, to be
taken evety 3 hours as needed with no daily maximum dose stated.
This could result in ingestion of 40,000 IU of vitamin A in a 24
hour period, approaching levels of acute toxicity. Neither formu-
lation warns about the risk of vitamin A toxicit)', nor that current
and former smokers should avoid its use, although pregnant and
breastfeeding women are cautioned not to ase the product.
VITAMIN C
Vitamin C, in high dosages, continues to be promoted for its
role in immune funaion and the common cold. The Food and
Drug Administration (FDA) has warned manufacturers against
making unlawáil marketing claims for OTC products in combina-
tion with vitamin C, citing insufficient substantiating data. Vitamin
C may be l^ally marketed to "support a healthy immune system" or
other structure-function claims. The prevention and treatment of
cold symptoms at 200 mg or more daily has been observed only in
people experiencing extreme climates or in athletes, such as skiers,
marathon runners, and soldiers in subarctic temperatures." As for a
vray to prevent, or treat, cancer, a recent review of 38 trials of vita-
min C (or vitamin E) for cancer prevention or treatment found little
evidence to support its use for this purpose.'
Although safe, diarrhea, nausea, vomiting, heartburn, gas-
trointestinal cramping, flushing, headache, or insomnia can occur
with acute administration of several grams vitamin C. Frequent
high dosages of 2 grams daily may cause urinary oxalate stones;
urate and cysteine stones have also occurred with long-term tise.'°
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VITAMIN D
Research on vitamin D has demonstrated potential ben-
efits beyond the prevention of osteoporosis. Better considered
a liormone, vitamin D consists of ergosterol and 7-dehydroc-
holesterol (provitamin D3). Multiple cells express vkamin D
receptors, including osteoblasts, muscle cells, ovarian and pros-
tate cells, circulating monocytes, pancreatic islet cells, and many
otbers. Vitamin D deficiency may be present among adults of
all ages, not only frail older adults living in nursing homes.
Among healthy older adults living independently, the incidence
of unrecognized vitamin D deficiency may reacb 40% to 50%.
Small clinical trials and many observational studies have
identified a range oí potential health benefits witb vitamin D,
although few are supported by evidence from large clinical
trials. Several mcra-analyses have reported that supplemental
vitamin D in dosages between 700 IU and 1000 IU are associ-
ated with a reduction of about 20% in the risk of felling in
older adults. The administration of dosages less than 700 IU of
vitamin D have not been associated with this potential benefit.
In addition, individuals with vitamin D concentrations of 82
nmol/L or higher had a 50% lower incidence of colorectal can-
cer than those with concentrations of 30 nmol/L or less in one
mcta-analysis. A case-control study from the Women's Health
Initiative reported that concentrations of vitamin D below 31
nmol/L were associated with a significantly increased risk for
invasive colorectal cancer.
The optimal intake of vitamin D remains controversial.
New dietary recommendations for vitamin D in adults are ex-
pected in 2010 from the institute of Medicine. Although vita-
min D toxicity is quite rare, clinicians should recognize that
many different OTC products now contain vitamin D. For
example, some glucosamine products include vitamin D in their
formulations. A consumer who consumes many different types
of OTC products may be getting 1000 IU of vitamin D daily
from each product.
In October 2008, tbe American Academy of Pediatrics and
tbe Institute of Medicine recommended doubling the adequate
intake of vitamin D 200 IU to a minimum of 400 IU per day for
infimts, children, and adolescents. The changes reflected tbe grow-
ing evidence that vitamin D intake will have lifelong benefits in
maintaining bone health as well as playing a potential role in tbe
prevention of chronic diseases, such as cancer. Although rare, cases
of rickets are reported in the United States, especially with the re-
emci^ence of breastfeeding, and can be botb prevented and treated
by supplemental vitamin D."
VITAMIN E
At least 10% of adults use 400 IU or more of vitamin E as
alpba-tocopberol daily, although evidence for the prevention
of cancer, CVD, and cognitive decline is lacking. Major ran-
domized, controlled trials do not demonstrate favorable clini-
cal outcomes with vitamin E. Tbe ATBC trial. Women's Health
Study, Heart Outcomes Prevention Evaluation (HOPE) study,
and Pbysician's Health Study II found no difference in car-
diovascular events or mortality. In tbe HOPE-TOO study,
patients taking vitamin E had an unexpected 13% increase in
heart iàilure.'^ Data regarding vitamin E and the prevention
of cancer is inconsistent, witb most trials showing no benefit.
Botb HOPE-TOO and Women's Health Study did not dem-
onstrate a reduction in the risk of cancer. The Selenium and
Vitamin E Cancer Prevention Trial (SELECT) also report no
reduction in prostate cancer in relatively healthy men. The
DATATOP study showed that vitamin E had no effect on pro-
gression of Parkinson's Disease. Two high quality trials of vita-
min E reported no benefit in patients with Alzheimer's disease
or mild cognitive impairment."
Although dosages of 100 mg to 800 mg vitamin E (ap-
proximately 150 to 1,200 IU) are taken without adverse ef-
fects, botb tbe ABTC study and tbe Physician's Health Study
II reported bemorrbagic stroke. Tbe use of high dosages of
vitamin E sbould be discouraged in patients taking antiplatelet
or anticoagulant tberapies, as well as other dietary supplements
witb antiplarelet properties.
VITAMIN K
Vitamin K is now frequently a component in MV and
MVMM formulations, especially those promoted as "senior for-
mulas" or for "bone bealtb." Combination calcium and vitamin
D products also commonly include vitamin K 20 meg to 80
meg per tablet. Vitamin K has been added because observational
studies suggested a decreased risk of fractures associated with
higher dietary intake. Clinical trials from Japan have also reported
reductions in fracture risk using pharmacologie dosages of
menaquinone-4. The activity of osteocatcin depends on tbe
gamma-carboxylation of three glutamate residues by vitamin K.
Vitamin K may also affect osteoprotegerin, a cytokine that binds
RANKL, potentially inbibiting the maturation of osteodasts and
decreasing bone résorption. Despite tbe evidence with vitamin
K and osteoporosis, patients taking warfarin sbould recognize
the potential for an interaction, especially if multiple products
containing larger amounts of vitamin K are being taken.
PYRIDOXINE, FOLIC ACID AND CYANOCOBALAMIN
Pyridoxine. folic acid, and cyanocobalamin frequently are
used in combination to prevent or self-treat CVD. While studies
have evaluated the effect of these vitamins on reducing homocys-
teine concentrations, the evidence does not support a reduction
of cardiovascular disease or mortality in otherwise healthy adults.
The American Heart Association does not recommend B vita-
min supplementation beyond tbat obtained from a balanced
diet for reduction of risk in heart disease and stroke.'''
For cancer prevention, findings are mixed. FoHc acid
supplementation in a multivitamin and dietary consumption
both show a reduction in colon cancer, however studies evalu-
ating risk witb otber cancers find no relationship. A recent study
from Norway, where there is no fortification of food, has raised
concerns about folic and vitamin B12 in patients with under-
lying ischémie heart disease. A significant increase risk of can-
cer and overall mortality was related to supplementation.'^
Tbe strongest evidence for supplemental folic acid 400 to
800 meg daily is in prevention of neural tube defects as part of
preconception planning. Those at high risk, sucb as women
taking anticonvulsant medications, are recommended to take
4 mg daily. The US Preventive Services Task Force advises pro-
viders to recommend folic acid to all women of childbearing
age since dosages of 400 to 800 meg daily are not barmful."*
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Pyridoxine in dosages of lOmg to 25mg every 8 hours has
provided relief of nausea and vomiting during the first ttimes-
ter, particularly in women with severe symptoms. The Ameri-
can College of Obstetrics and Gynecology continues to rec-
ommend pyridoxine, with or without doxylamine, as a first-
line option.'''
RiBOFLAVIN
Riboflavin is used as a method of migraine prophylaxis at
dosages up to 400 mg per day. A placebo-controlled double
blind study in adults found riboflavin significantly reduces fre-
quency and duration of migraines, while another small trial
found it equal to beta-blockers in preventing attacks. More
studies are needed to fully understand the extent of its efficacy,
although its safety profile is quite favorable. At this dosage, pa-
tients may experience frequent urination, change in urine color
to yellow or orange, or diarrhea. It may be used as a second-
line agent for migraine prevention.'^' "
NiACIN
Constmiers use niadn, or nicotinic acid, to treat elevated lipid
levels. Older, large clinical trials have shown that niacin may re-
duce cardiovascular events and overall mortality when used in
pharmacologie dosages between lOOOmg and 4000 mg daily. At
these dosages, low density Upoprotein (LDL) cholesterol levels
are decreased by 5% tu 25%, while triglycérides are reduced by
20% to 50%. UnJike statins, niacin also increases higji density
lipoprotein (HDL) cholesterol by 15% to 35%.
A review of OTC niacin preparations found "no flush"
products contain inosotil hexaniacinate, a prodrug of nicotinic
acid, that gradually hydrolyzes therefore reducing flush. Its peak
concentration of nicotinic acid is low compared with other for-
mulations and no clinical studies have demonstrated its effec-
tiveness for the treatment of dyslipidemias. OTC extended-
release formulations oí niacin offer ease of dosing and less flush-
ing, although simple self-care measures can be applied to the
less expensive immediate-release products to help reduce this.
These include slowly titrating dose, administration after meals,
avoiding hot drinks or alcohol, or incorporating aspirin 81 mg
30 minutes prior to niacin.
Niacin is inappropriate for the self-treatment of dyslipidemia.
Hepatotoxicity ¡s more common with extended-release prepara-
tions which require close monitoring. Other adverse effects in-
clude headache, nausea, vomiting, peptic ulcer disease, and di-
arrhea. Patients with diabetes who take 4.5 grams daily for 5
weeks had an average increase of plasma glucose by 16% and
hemoglobin Al C by 21%. Daily dosages of 2.5 grams or less
increase plasma glucose by 4% to 5% and hemoglobin Al C by
0.3% or less. Effects are dose-dependent and patients with dia-
betes should be monitored carefully. The risk of hyperuricemia
occurs at dosages greater than 2 grams daily, and individuals
with a history of severe gout should avoid niacin completely.^"
PRODUCT QUALITY
Dietary supplement content is dependent upon the prod-
uct and is not regulated by the FDA. If a supplement is war-
ranted, consumers should look for products with US Pharma-
copeia Verification or Consumer Labs Quality Seal. These in-
MEDICINE & HEALTH/RHODE ISLAND
dependent agencies test for labeled ingredients and lack of
contaminants within the product. Note: these seals do not in-
dicate efficacy or safety of that particular supplement.
SUMMARY
American adults take many types of vitamin supplements,
despite limited evidence of their efficacy, especially in prevent-
ing chronic diseases such as cardiovascular disease and cancer.
Supplements contain significant amounts of vitamins when
consumed from multiple sources. Excess consumption of some
vitamins may have detrimental health effects. Use of MMVM
products appears to be safe; however, clinical outcomes have
not been established. Although vitamin D and preconception
folie acid may be appropriate for self care, a health care pro-
vider should monitor other vitamin supplements for disease
prevention, such as niacin. Beyond supplementation as treat-
ment for vitamin deficiencies, evidence is lacking.
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